BriaCell to Investigate Alleged Illegal Trading of Public Securities
January 23 2023 - 8:41AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company specializing in targeted immunotherapies for cancer,
announced today that it has approved measures to address alleged
illegal trading activity of its publicly traded securities. The
Company believes that certain individuals and/or companies may have
engaged in manipulative and/or suspected illegal trading practices
that may have artificially depressed its share price. As a result,
BriaCell is implementing a plan to address this issue which may
include legal action.
BriaCell is working to build one of the leading
immuno-oncology companies in the biotech sector with a singular
focus on commercializing our novel immunotherapy approach for
cancer patients. While our clinical team remains dedicated to
developing these desperately needed therapies, the Company
recognizes that recent milestones have been achieved with the
support of loyal investors who are instrumental in the ongoing
development of our assets. By taking action to protect the
interests of our shareholders, we are also protecting the interests
of the Company and the tens of thousands of cancer patients in need
of effective treatment options. To this end, BriaCell is pursuing
avenues to address alleged illegal activities carried out by
various parties potentially working collusively with the intent of
depressing the Company’s share price while undermining the interest
of our shareholders.
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology-focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Examples of
forward-looking statements in this news release include statements
that the Company makes regarding the Company's plans to address
alleged illegal activities carried out by various parties
potentially working collusively with the intent of depressing the
Company’s share price which may include legal action.
Forward-looking statements are based on BriaCell’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully under the heading “Risks and
Uncertainties” in the Company's most recent Management’s Discussion
and Analysis, under the heading "Risk Factors" in the Company's
most recent Annual Information Form, and under “Risks and
Uncertainties” in the Company's other filings with the Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission, all of which are available under the Company's
profiles on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov. Forward-looking statements
contained in this announcement are made as of this date, and
BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024